Lower than every week after Eisai and Biogen gained accelerated approval from the FDA for his or her Alzheimer’s drug lecanemab, Govt Editor Drew Armstrong spoke one-on-one with Eisai US CEO Ivan Cheung, who additionally leads the corporate’s Alzheimer’s efforts. This transcript has been edited for brevity and readability.

Drew Armstrong:

Good luck everybody. I am Drew Armstrong, govt editor at Endpoints Information, and I am very happy to be joined by Ivan Cheung from Eisai. He runs the US enterprise and oversees the Alzheimer’s program there. Clearly, you all had huge information final week with the accelerated approval of Lecanemab, and congratulations on that. It is clearly a giant second for the sector, a giant second on your firm. I need to bounce proper in as a result of we’ve half-hour and so much to cowl. I’m extremely excited to get this chance to speak with you. Now, I am in San Francisco, you are in New Jersey. Sorry we won’t meet in individual, however plenty of information from you all. You’ve acquired this expedited approval.

Endpoints Premium

Premium subscription required

Unlock this text and different advantages by subscribing to one of many paid plans.

Supply hyperlink